Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT Combined With Erlotinib vs WBRT for EGFR Wild Type NSCLC Brain Metastases
NCT02556593Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung carcinoma (NSCLC), sponsored by Sun Yat-sen University. Started Sep 2015; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT02556593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556593.